Abstract:Background: Cervical cancer (CC) is the most common gynecological malignancy. Recently, an increasing number of studies have indicated that osteopontin (OPN) is a promising diagnostic and prognostic biomarker for CC. However, the biological role and detailed mechanism of OPN in CC remain unclear. Methods: The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets and a clinical sample microarray were used in our study. To identify the clinicopathological characteristics of OPN in CC, we compared the expression of OPN between normal and CC tissue samples and analyzed the correlations between OPN expression and multiple clinicopathological features. To identify biological processes involving OPN, OPN-associated genes were screened with Pearson correlation analysis and applied in hallmark gene set enrichment analysis (GSEA). Additionally, leukocyte infiltration was evaluated based on OPN expression. Finally, OPN-related signaling pathways were identified by GSEA. Results: OPN expression was higher in CC samples than in normal tissue samples and positively correlated with age, FIGO stage, tumor size, lymphovascular invasion and an unfavorable prognosis. OPN-associated genes were mainly enriched in the immune response, and increased OPN expression was accompanied by increased M2 macrophage infiltration. Additionally, OPN was correlated with hypoxia, high glycolytic metabolism, apoptosis, angiogenesis, epithelial-mesenchymal transition and multiple signaling pathways (the p53 pathway, the PI3K/Akt pathway, IL6/STAT3 signaling, mTORC1 signaling and KRAS signaling). Conclusion: Our study showed that OPN is involved in immunological activities and multiple tumor processes, identifying it as a potential therapeutic target and useful prognostic factor in CC patients.

Osteopontin promotes tumor growth and metastasis and GPX4-mediated anti-lipid peroxidation in triple-negative breast cancer by activating the PI3k/Akt/mTOR pathway

Osteopontin As a Multifaceted Driver of Bone Metastasis and Drug Resistance

Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1alpha up-regulation and MMP9 activation

Abstract 2695: Osteopontin Regulated Epithelial-Mesenchymal Transition Via PI3K/AKT Signaling Pathway in Hepatocellular Carcinoma.

Overexpression of Osteopontin Induces Angiogenesis of Endothelial Progenitor Cells Via the Avβ3/pi3k/akt/enos/no Signaling Pathway in Glioma Cells

Osteopontin As Potential Biomarker and Therapeutic Target in Gastric and Liver Cancers.

The Role of Osteopontin in Tumor Progression Through Tumor-Associated Macrophages

Osteopontin Promotes Hepatocellular Carcinoma Invasion by Up-Regulating MMP-2 and Upa Expression.

The role of osteopontin in the progression of solid organ tumour

Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation

Clinical and in Vitro Analysis of Osteopontin As a Prognostic Indicator and Unveil Its Potential Downstream Targets in Bladder Cancer

Hypoxia‐driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial–mesenchymal transition and cancer stem cell‐like properties by modulating forkhead box protein M1

GluOC promotes proliferation and metastasis of TNBC through the ROCK1 signaling pathway

Osteopontin Promotes Metastasis of Intrahepatic Cholangiocarcinoma Through Recruiting MAPK1 and Mediating Ser675 Phosphorylation of Β-Catenin

OPN up-regulated proliferation and invasion of head and neck squamous cell carcinoma through the p38MAPK signaling pathway

Human Osteopontin: Potential Clinical Applications In Cancer

Osteopontin is a therapeutic target that drives breast cancer recurrence

Endocrine regulation and metabolic mechanisms of osteopontin in the development and progression of osteosarcoma, metastasis and prognosis

Biological and Clinicopathological Characteristics of OPN in Cervical Cancers

Osteopontin Promotes Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Through Regulating Vimentin.

Osteopontin is A Promoter for Hepatocellular Carcinoma Metastasis: A Summary of 10 Years of Studies